Katharina Schieber1, Alexander Niecke2, Franziska Geiser3, Yesim Erim4, Corinna Bergelt5, Antje Büttner-Teleaga6, Imad Maatouk7, Barbara Stein8, Martin Teufel9, Martin Wickert10, Alexander Wuensch11, Joachim Weis12. 1. University Hospital of Erlangen, Department of Psychosomatic Medicine and Psychotherapy, Friedrich-Alexander-University Erlangen-Nürnberg, Schwabachanlage 6, D-91054, Erlangen, Germany. Electronic address: katharina.schieber@gmail.com. 2. University Hospital Cologne, Department of Psychosomatics and Psychotherapy & Centre Psychooncology (CePO), Kerpener Str. 62, D-50937, Cologne, Germany. 3. University of Bonn, Clinic for Psychosomatic Medicine and Psychotherapy, Sigmund-Freud-Str.25, D-53127, Bonn, Germany. 4. University Hospital of Erlangen, Department of Psychosomatic Medicine and Psychotherapy, Friedrich-Alexander-University Erlangen-Nürnberg, Schwabachanlage 6, D-91054, Erlangen, Germany. 5. Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Center for Psychosocial Medicine, Martinistrasse 52, D-20246, Hamburg, Germany. 6. Institute of Cognitive Science, Woosuk University, 565-701, Samrye-up, Wanju-gun, Jeonbuk, Republic of Korea. 7. Medical University Hospital Heidelberg, Department of General Internal Medicine and Psychosomatics, Im Neuenheimer Feld 410, D-69120, Heidelberg, Germany. 8. Department of Psychosomatic Medicine and Psychotherapy, Paracelsus Medical University, Nuremberg General Hospital, Prof.-Ernst-Nathan-Straße 1, D-90419, Nuremberg, Germany. 9. University of Duisburg-Essen, Department of Psychosomatic Medicine and Psychotherapy, Comprehensive Cancer Center Essen (WTZ) and LVR Hospital, Virchowstr. 174, D-45147, Essen, Germany. 10. Medical University Hospital Tuebingen, Universitätsklinikum Tübingen, Comprehensive Cancer Center Tübingen-Stuttgart, Herrenberger Str. 23, D-72070, Tübingen, Germany. 11. Clinic for Psychosomatic Medicine and Psychotherapy, Medical Center Freiburg, Faculty of Medicine, University Freiburg in Cooperation with Outpatient Support for Cancer Patients, Comprehensive Cancer Center Freiburg, Hauptstr. 5a, D-79104, Freiburg, Germany. 12. Comprehensive Cancer Center, Department Self-help Research, Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 49, D-79106, Freiburg, Germany.
Abstract
OBJECTIVE: The study aimed to examine the 12-month course of cancer-related insomnia (CRI) and to identify possible predictors for the prevalence and persistence of CRI. METHODS: This longitudinal multicenter study included N = 405 patients with cancer (56% females, mean age: 58.6 years). CRI was measured by the Insomnia Severity Index (ISI). Socio-demographic and clinical data, as well as psychological parameters (Distress Thermometer, PHQ-9, GAD-7, and EORTC-Fatigue), were assessed at baseline (T1) and 12 months later (T2). RESULTS: In our sample, a high prevalence of relevant insomnia symptoms (49.4%, ISI > 7) was found, while a clinical insomnia diagnosis was verified in 12.8% (ISI > 14). When insomnia was present at T1, this problem was persistent after one year in 64%. At T2, however, significantly more women suffered from insomnia symptoms (53.3% women vs. 39.3% men; p = 0.003). Insomnia was associated with many clinical and psychological parameters, especially with fatigue (r = 0.5). Multiple regression analysis revealed that, in women, only insomnia at T1 was a significant predictor for insomnia at T2 (R2 = 0.40; F(5) = 12.5; p < 0.001), whereas in men insomnia, depressive symptoms and the use of psychotropic drugs at T1 predicted the extent of insomnia at T2 (R2 = 0.28; F(7) = 9.5; p < 0.001). In all participants, levels of distress, depression, and anxiety decreased from T1 to T2 (p's < 0.016). CONCLUSION: Insomnia is a common disorder in cancer patients. Although medical and psychological parameters improved during the 12-month course of cancer treatment, our results show that insomnia is highly persistent, especially in women. This indicates that adequate support for those affected is needed. CLINICAL TRIAL REGISTRATION NUMBER: DRKS00004860.
OBJECTIVE: The study aimed to examine the 12-month course of cancer-related insomnia (CRI) and to identify possible predictors for the prevalence and persistence of CRI. METHODS: This longitudinal multicenter study included N = 405 patients with cancer (56% females, mean age: 58.6 years). CRI was measured by the Insomnia Severity Index (ISI). Socio-demographic and clinical data, as well as psychological parameters (Distress Thermometer, PHQ-9, GAD-7, and EORTC-Fatigue), were assessed at baseline (T1) and 12 months later (T2). RESULTS: In our sample, a high prevalence of relevant insomnia symptoms (49.4%, ISI > 7) was found, while a clinical insomnia diagnosis was verified in 12.8% (ISI > 14). When insomnia was present at T1, this problem was persistent after one year in 64%. At T2, however, significantly more women suffered from insomnia symptoms (53.3% women vs. 39.3% men; p = 0.003). Insomnia was associated with many clinical and psychological parameters, especially with fatigue (r = 0.5). Multiple regression analysis revealed that, in women, only insomnia at T1 was a significant predictor for insomnia at T2 (R2 = 0.40; F(5) = 12.5; p < 0.001), whereas in meninsomnia, depressive symptoms and the use of psychotropic drugs at T1 predicted the extent of insomnia at T2 (R2 = 0.28; F(7) = 9.5; p < 0.001). In all participants, levels of distress, depression, and anxiety decreased from T1 to T2 (p's < 0.016). CONCLUSION:Insomnia is a common disorder in cancerpatients. Although medical and psychological parameters improved during the 12-month course of cancer treatment, our results show that insomnia is highly persistent, especially in women. This indicates that adequate support for those affected is needed. CLINICAL TRIAL REGISTRATION NUMBER: DRKS00004860.
Authors: Carol Chunfeng Wang; Ellen Yichun Han; Mark Jenkins; Xuepei Hong; Shuqin Pang; Lisa Whitehead; Deborah L Kirk; Anne Williams Journal: Palliat Care Soc Pract Date: 2022-01-10
Authors: Charlotte Grégoire; Nolwenn Marie; Corine Sombrun; Marie-Elisabeth Faymonville; Ilios Kotsou; Valérie van Nitsen; Sybille de Ribaucourt; Guy Jerusalem; Steven Laureys; Audrey Vanhaudenhuyse; Olivia Gosseries Journal: Front Psychol Date: 2022-02-10
Authors: Thomas Schulte; Dirk Hofmeister; Anja Mehnert-Theuerkauf; Tim Hartung; Andreas Hinz Journal: Support Care Cancer Date: 2021-05-29 Impact factor: 3.603